Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 51 peer-reviewed journal articles Updated

Understanding Livedoid Vasculopathy: An Introduction

At a Glance

Livedoid Vasculopathy (LV) is a rare, chronic skin condition caused by tiny blood clots in the small vessels of the lower legs and feet. It leads to painful ulcers and scarring but is manageable with blood thinners. Importantly, LV is a clotting disorder, not an inflammatory condition like vasculitis.

Finding out you have Livedoid Vasculopathy (LV) can feel overwhelming, especially since you may have never heard of it before your diagnosis. It is a rare, chronic skin condition that primarily affects the lower legs and feet [1][2]. While it can be painful and frustrating, understanding the nature of the disease is the first step toward managing it effectively. It is important to know that LV is not contagious and, with the right care team, many patients find relief and healing [3][4].

What is Livedoid Vasculopathy?

In plain language, Livedoid Vasculopathy is a condition where tiny blood clots form in the small blood vessels of the skin [4][5]. These clots block the flow of blood (a process called vaso-occlusion), which prevents oxygen and nutrients from reaching the skin tissue [6][7]. This lack of blood flow is what causes the characteristic pain and skin changes associated with the disease.

Not a Vasculitis

A common point of confusion is whether LV is a type of “vasculitis.” While the names sound similar, they are fundamentally different:

  • Vasculitis is an inflammatory condition where the immune system attacks the blood vessel walls [8].
  • Livedoid Vasculopathy is a thrombotic (clotting) condition. The primary problem is the formation of clots, not inflammation [6][7].

This distinction is vital because the treatments are different. While vasculitis is often treated with drugs that suppress the immune system, LV is primarily managed with anticoagulants (blood thinners) to prevent clots from forming [8][5].

The Three Main Signs

Doctors often look for a “triad” of three classic symptoms when identifying LV [4][9]:

  1. Livedo Racemosa: This is a persistent, purple or reddish lace-like pattern on the skin. Unlike standard “livedo reticularis,” which may come and go with the cold, livedo racemosa is often permanent and has a broken, irregular pattern [4][10].
  2. Painful Ulcers: Small, shallow sores that are often intensely painful, even when they look small [3][11]. These ulcers usually appear around the ankles or on the tops of the feet.
  3. Atrophie Blanche: As the ulcers heal, they leave behind smooth, white, star-shaped scars surrounded by tiny red dots (dilated blood vessels) [4][9].

Why is it So Rare?

LV is considered a rare disease, meaning very few people are diagnosed with it each year. Because it is uncommon, there are no large-scale statistics on exactly how many people have it [12][13]. Most of what medical science knows comes from small groups of patients and individual case reports [12][2].

This rarity often leads to a “diagnostic odyssey”—a long period where patients go from doctor to doctor before getting the right answer. If you feel frustrated or anxious about the time it took to get diagnosed, know that those feelings are a very common and valid reaction to dealing with a rare condition [13][14]. Your doctor will typically use biopsies and blood tests to confirm the condition.

Moving Forward with Confidence

While LV is a chronic condition, it is manageable. Here are a few “stabilizing facts” to keep in mind:

01

Building Your LV Care Team

Learn how to build your Livedoid Vasculopathy (LV) care team. Discover why you need a dermatologist, hematologist, and rheumatologist for effective treatment.

02

Living Well with LV: Daily Management and Outlook

Learn how to manage Livedoid Vasculopathy (LV) daily. Discover tips for painful wound care, ischemia pain relief, avoiding infection, and emotional support.

The goal of treatment is to stop the clotting process, which allows the skin to heal and prevents new ulcers from forming [1][5]. By working closely with a specialist, you can develop a plan that addresses both the physical symptoms and the emotional impact of the diagnosis.

Common questions in this guide

Is Livedoid Vasculopathy the same as vasculitis?
No. While the names sound similar, they are fundamentally different. Vasculitis is an inflammatory condition where the immune system attacks blood vessel walls. Livedoid Vasculopathy is a clotting condition where tiny blood clots block blood flow to the skin.
What are the main symptoms of Livedoid Vasculopathy?
Doctors typically look for three classic signs: a permanent purple lace-like pattern on the skin (livedo racemosa), intensely painful shallow ulcers around the ankles or feet, and smooth, white, star-shaped scars (atrophie blanche) that form as the ulcers heal.
How is Livedoid Vasculopathy treated?
Because it is a clotting disorder rather than an inflammatory one, LV is primarily treated with anticoagulants, or blood thinners. These medications stop the clotting process, which relieves pain, helps existing ulcers heal, and prevents new ones from forming.
Why does it take so long to get a Livedoid Vasculopathy diagnosis?
LV is considered a rare disease, so many healthcare providers may not immediately recognize it. It often requires a diagnostic odyssey involving biopsies, specialized blood tests, and consultations with specialists like dermatologists or hematologists to confirm.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I working with a dermatologist or hematologist who has experience treating Livedoid Vasculopathy specifically?
  2. 2.Has a 'hypercoagulable workup' (a detailed blood panel) been ordered to check for underlying clotting disorders?
  3. 3.Since this is a vaso-occlusive condition rather than vasculitis, why is anticoagulation the preferred treatment over immunosuppressants for me?
  4. 4.What are my options for managing the intense pain during an active flare-up?
  5. 5.How will we monitor the healing of my ulcers and the progress of the 'atrophie blanche' scars?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Long-Term Efficacy of Guideline-Followed Treatment in Patients with Livedoid Vasculopathy: A Single-Center Study.

    Hillgruber C, Mitschang C, Eveslage M, et al.

    Advances in wound care 2025; doi:10.1177/21621918251395013.

    PMID: 41264385
  2. 2

    Clinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.

    Shah SR, Vyas HR, Doshi YJ, Shah BJ

    Indian dermatology online journal 2022; (13(6)):771-774 doi:10.4103/idoj.idoj_182_22.

    PMID: 36386750
  3. 3

    Treatment outcomes in patients of livedoid vasculopathy following antithrombotic therapy: A retrospective observational study.

    Gupta P, Thakur V, Behera B, et al.

    Indian journal of dermatology, venereology and leprology 2026; 1-9.

    PMID: 41655089
  4. 4

    Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.

    Weishaupt C, Strölin A, Kahle B, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(9)):1784-1791 doi:10.1111/jdv.15639.

    PMID: 31009111
  5. 5

    Lymphocytic vasculitis in livedoid vasculopathy: A report of 137 cases.

    Yuan Y, Liu Y, Ban F, et al.

    Journal of cutaneous pathology 2024; (51(2)):155-162 doi:10.1111/cup.14546.

    PMID: 37837185
  6. 6

    Inflammatory and vaso-occlusive ulcers: Part I - Clinical presentation and diagnosis.

    Shakshouk H, Hines A, Kody S, et al.

    Journal of the American Academy of Dermatology 2024; (91(6)):1035-1048 doi:10.1016/j.jaad.2024.01.083.

    PMID: 38432459
  7. 7

    Livedoid vasculopathy: how to diagnose and how to treat?

    Lipsker D

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(9)):1627-1628 doi:10.1111/jdv.15830.

    PMID: 31468610
  8. 8

    Retiform non-blanchable purpuric plaques in a patient with systemic lupus erythematosus.

    Grinnell M, Bath A, DiMaio D, et al.

    Lupus 2019; (28(8)):1013-1016 doi:10.1177/0961203319847274.

    PMID: 31126212
  9. 9

    Identification of Challenging Diagnostic Factors in Livedoid Vasculopathy: A Retrospective Study.

    Qi F, Gao Y, Jin H

    Clinical, cosmetic and investigational dermatology 2024; (17()):1747-1756 doi:10.2147/CCID.S466449.

    PMID: 39109220
  10. 10

    Dermoscopic features of livedoid vasculopathy.

    Hu SC, Chen GS, Lin CL, et al.

    Medicine 2017; (96(11)):e6284 doi:10.1097/MD.0000000000006284.

    PMID: 28296736
  11. 11

    Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

    Gao Y, Jin H

    The Journal of dermatological treatment 2022; (33(1)):178-183 doi:10.1080/09546634.2020.1737634.

    PMID: 32116074
  12. 12

    Livedoid vasculopathy.

    Leeolou MC, Rieger KE, Yeh JE

    Dermatology online journal 2023; (29(5)) doi:10.5070/D329562414.

    PMID: 38478650
  13. 13

    Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis.

    Renner R, Dissemond J, Goerge T, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(11)):1884-1889 doi:10.1111/jdv.14190.

    PMID: 28252815
  14. 14

    Livedoid vasculopathy and its association with genetic variants: A systematic review.

    Gao Y, Jin H

    International wound journal 2021; (18(5)):616-625 doi:10.1111/iwj.13563.

    PMID: 33686673
  15. 15

    Clinical and patient reported treatment outcomes of livedoid vasculopathy: a systematic review.

    Gipple MO, Throckmorton SK, Gabo VB, et al.

    Clinical and experimental dermatology 2025; (50(4)):856-858 doi:10.1093/ced/llae377.

    PMID: 39298646
  16. 16

    A case report and literature review of livedoid vasculopathy in children.

    Qu J, Hao Z, Junli W, Yu S

    Frontiers in pediatrics 2025; (13()):1537133 doi:10.3389/fped.2025.1537133.

    PMID: 40438782
  17. 17

    Addressing Diagnostic Challenges in Livedoid Vasculopathy: A Case Report on Interdisciplinary Management.

    Ríos Padín J, Rivera Rodríguez DM, Nuñez Morales J, Álvarez Cardín N

    Cureus 2024; (16(10)):e72554 doi:10.7759/cureus.72554.

    PMID: 39606545
  18. 18

    Livedoid vasculopathy - A diagnostic and therapeutic challenge.

    Burg MR, Mitschang C, Goerge T, Schneider SW

    Frontiers in medicine 2022; (9()):1012178 doi:10.3389/fmed.2022.1012178.

    PMID: 36262273

This page is for informational purposes only and does not replace professional medical advice. Always consult your dermatologist or hematologist regarding the diagnosis and treatment of Livedoid Vasculopathy.

Get notified when new evidence is published on Livedoid vasculopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.